Previous 10 | Next 10 |
Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday. The clinical-stage biotech specializes in antibody therapies to treat cancer. The stock has been falling all week. On Monday, the company released early phase 2 data on Adagrasib to treat non-small ce...
Mirati Therapeutics ( NASDAQ: MRTX ) is down 30% in Wednesday afternoon trading, a day after closing off 23% . The biotech Tuesday released phase 2 data on its candidate adagrasib in combination with Merck's ( MRK ) Keytruda (pembrolizumab) in non-small cell lung cancer. ...
Shares of Mirati Therapeutics (NASDAQ: MRTX) fell more than 20% in the early afternoon on Tuesday. The clinical-stage biotech company focuses on oncology therapies. It saw its shares plunge more than $19 from their closing price on Monday. The slump happened after the company anno...
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) PR Newswire Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promisi...
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study PR Newswire Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Checkpoint Inhibi...
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO PR Newswire SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology co...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com Mirati Therapeutics (NASDAQ: MRTX ) stock is a hot topic on Wednesday as the cancer drugmaker considers a potential takeover . According to insider sources, several large ...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billi...
Mirati Therapeutics, Inc. (MRTX) Q3 2022 Earnings Conference Call November 08, 2022, 04:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - Chief Executive Officer Charles Baum - President, Founder & Head of Research &am...
Mirati Therapeutics press release ( NASDAQ: MRTX ): Q3 GAAP EPS of -$3.09 beats by $0.40 . Revenue of $5.4M (-92.5% Y/Y) beats by $4.03M . MRTX's revenue of $71.8M in Q3 last year was due to the recognition of $66.6M of revenue associated with the transfer...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...